Other Routine +

NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology

NuGen Files Needle-Free Nozzle Patent as Stock Tests Multi-Year Lows

By The Northwire Desk — AI Analysis Mar 25, 2026 · 17:15 NGMD · 0.025 Nugen Medical Devices Inc.

Executive Summary

NuGen Medical Devices filed a patent for a Ready-to-Fill (RTF) COP/COC injection nozzle, branded as the Prefilled Nozzle (PFN) platform.
The PFN is designed for needle-free, high-pressure jet injection of complex biologics (GLP-1s, growth hormones, monoclonal antibodies) and is compatible with standard aseptic fill-finish lines.
The system pairs the disposable nozzle with a reusable auto-injector that automatically adjusts to 0.5 mL or 1.0 mL formats and delivers the full dose in under one second.
NuGen has partnered with Gerresheimer Medical Plastics to utilize fully automated RTF production lines, aiming to minimize manufacturing changes for pharma partners.
Pre-clinical testing of PFN samples is targeted for completion by year-end 2026, with a fixed-dose auto-injector launch planned for 2027.
Management highlights ESG benefits, reduced drug waste, elimination of needle-stick injuries, and avoidance of needle-lumen chemical interactions as key value propositions for potential pharmaceutical partners.

Material Impact

The patent filing represents an incremental R&D milestone rather than a near-term commercial catalyst. It extends NuGen's existing needle-free portfolio but does not generate immediate revenue or alter the current commercial trajectory of the InsuJet or EziAutoJector products.
The timeline to commercialization (pre-clinical by late 2026, product launch in 2027) introduces significant execution and regulatory risk. The market has already priced in early-stage development uncertainty, as evidenced by the stock's prolonged downtrend.
The Gerresheimer partnership is strategically sound for manufacturing scalability, but it does not guarantee pharma adoption or licensing deals. The news is positive for long-term pipeline diversification but routine in the context of medtech development cycles.
No immediate financial impact, dilution event, or regulatory approval is attached to this release. The announcement aligns with the company's stated 2025-2026 R&D roadmap.

NGMD · Price

Company Overview

NuGen Medical Devices develops and commercializes needle-free drug delivery systems.
Flagship commercial product: InsuJet, a needle-free insulin delivery system approved in 42 countries.
UK commercial partner: EziAutoJector Ltd., which recently secured NHS drug tariff approval for reimbursable dispensing of its needle-free insulin device and accessories.
Pipeline: Prefilled Nozzle (PFN) platform targeting high-viscosity biologics, currently in pre-clinical development with a 2027 commercial launch target.
The company operates in a highly competitive medical device space, relying on clinical differentiation, regulatory approvals, and strategic manufacturing partnerships to scale.

More from Nugen Medical Devices Inc.